SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials#United_States#New_Haven#XingImaging#SynuSight#ABLi_Therapeutics
SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials
A strategic partnership among SynuSight Biotech, ABLi Therapeutics, and XingImaging aims to enhance clinical trials of risvodetinib through advanced imaging techniques for Parkinson's disease.
third-news.com
January 5, 2026 at 1:12 PM
SynuSight, ABLi Therapeutics, and XingImaging Collaborate on Alpha-Synuclein PET Imaging for Parkinson's Trials#United_States#New_Haven#XingImaging#SynuSight#ABLi_Therapeutics